Form 4: Cathy Smith Acquires Boston Scientific Stock Units

Cathy R. Smith, a Director at Boston Scientific Corp., acquired deferred stock units valued at approximately $340,000 on May 7, 2026.

Summary

• Cathy R. Smith, a Director of Boston Scientific Corp., acquired a total of 6,009 deferred stock units on May 7, 2026.
• These units represent a commitment to issue shares of Boston Scientific common stock.
• The acquisition includes 3,800 units valued at $215,000 and 2,209 units valued at $125,000.
• The 3,800 units are an annual equity award that vests upon the next annual meeting and will be issued upon separation from the Board.
• The 2,209 units were granted in lieu of 100% of the annual cash compensation and also vest upon the next annual meeting, with shares issued upon separation from the Board.
• Following these transactions, Smith beneficially owns 4,679 direct shares from the first grant and 6,888 direct shares from the second grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine compensation and insider activity rather than significant new financial information or strategic shifts.

Positives

• Director Cathy R. Smith has received a significant equity award, indicating continued commitment and alignment with the company's performance.
• The equity awards are structured to vest over time and upon separation from the board, aligning long-term incentives.
• The company is utilizing stock units in lieu of cash compensation, potentially preserving cash for operations or investment.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the deferred stock units is subject to the future market price of Boston Scientific common stock.
• Vesting and issuance of shares are contingent upon the reporting person's continued service and separation from the Board of Directors.

Future Outlook

The future outlook for the acquired deferred stock units depends on the performance of Boston Scientific's common stock and the reporting person's continued service.

Management Comments

• The filing details the structure of equity awards granted to Director Cathy R. Smith, including their valuation and vesting conditions.
• The awards are part of the company's Non-Employee Director Deferred Compensation Plan.

Industry Context

StockSavvy.ai notes that the issuance of deferred stock units to directors is a common practice in the medical device industry to align executive compensation with shareholder interests and long-term company performance.

Corporate Governance

Related Party Transactions

• The acquisition of deferred stock units by Director Cathy R. Smith represents a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: The issuance of stock units dilutes existing share ownership slightly, but aligns director compensation with company performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Shares of common stock will be issued to the reporting person following her separation from Board of Director service.
• The deferred stock units vest in full upon the next annual meeting of stockholders.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Stock Options, Deferred Stock Units, Equity Award, Director Compensation, Beneficial Ownership, SEC Filing